ZA941308B - Bisacodyl dosage form - Google Patents

Bisacodyl dosage form

Info

Publication number
ZA941308B
ZA941308B ZA941308A ZA941308A ZA941308B ZA 941308 B ZA941308 B ZA 941308B ZA 941308 A ZA941308 A ZA 941308A ZA 941308 A ZA941308 A ZA 941308A ZA 941308 B ZA941308 B ZA 941308B
Authority
ZA
South Africa
Prior art keywords
colon
bisacodyl
dosage form
lumen
small intestine
Prior art date
Application number
ZA941308A
Other languages
English (en)
Inventor
Paula Denise Davis
Douglas Joseph Dobrozsi
Gary Robert Kelm
Kenneth Gary Mandel
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of ZA941308B publication Critical patent/ZA941308B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epoxy Compounds (AREA)
ZA941308A 1993-02-26 1994-02-25 Bisacodyl dosage form ZA941308B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2341293A 1993-02-26 1993-02-26

Publications (1)

Publication Number Publication Date
ZA941308B true ZA941308B (en) 1994-09-30

Family

ID=21814950

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA941308A ZA941308B (en) 1993-02-26 1994-02-25 Bisacodyl dosage form

Country Status (20)

Country Link
US (1) US5670158A (pt)
EP (1) EP0686034B1 (pt)
JP (1) JP3725539B2 (pt)
CN (1) CN1047075C (pt)
AT (1) ATE201991T1 (pt)
AU (1) AU6251094A (pt)
BR (1) BR9405836A (pt)
CA (1) CA2156726C (pt)
CZ (1) CZ286051B6 (pt)
DE (1) DE69427466T2 (pt)
DK (1) DK0686034T3 (pt)
ES (1) ES2157253T3 (pt)
GR (1) GR3036042T3 (pt)
HU (1) HUT72975A (pt)
IL (1) IL108705A (pt)
PL (1) PL176846B1 (pt)
PT (1) PT686034E (pt)
SK (1) SK104895A3 (pt)
WO (1) WO1994018973A1 (pt)
ZA (1) ZA941308B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US6028190A (en) 1994-02-01 2000-02-22 The Regents Of The University Of California Probes labeled with energy transfer coupled dyes
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
CA2271560C (en) * 1996-11-15 2003-09-23 Mayo Foundation For Medical Education And Research Pharmaceutical dosage form for colonic delivery
AR017512A1 (es) * 1997-08-22 2001-09-12 Smithkline Beecham Corp Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
IT1296980B1 (it) * 1997-12-17 1999-08-03 Istituto Pirri S R L Capsula doppia come forma farmaceutica per la somministrazione di principi attivi in terapie multiple
DE19913606A1 (de) * 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
CA2371940C (en) * 1999-03-31 2008-07-15 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
CN1529587B (zh) * 2001-05-30 2010-05-12 欧洲凯尔特公司 含有粪便软化剂泊洛沙姆和包有肠溶衣的比沙可定颗粒的药物组合物
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
US20160184358A9 (en) * 2002-07-15 2016-06-30 George M. Halow Bowel cleansing composition
US7291324B2 (en) * 2002-10-22 2007-11-06 Braintree Laboratories Inc. Method of bowel cleansing
PT2279729T (pt) * 2003-07-17 2016-09-22 Banner Life Sciences Llc Preparações de libertação controlada
KR101323478B1 (ko) * 2004-03-10 2013-10-31 다이쇼 세이야꾸 가부시끼가이샤 수난용성 약물 배합 고형 제제
DK1976520T3 (da) * 2005-12-29 2011-06-27 Braintree Lab Et sæt omfattende et osmotisk laksativ og et stimulerende laksativ til forberedelse af kolon til virtuel kolonskopi
US8211417B1 (en) 2009-10-31 2012-07-03 Harry Snady Method of bowel cleansing
WO2014016671A2 (en) 2012-07-27 2014-01-30 Redhill Biopharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation
DE102014017936A1 (de) 2014-12-05 2016-06-09 Tracto-Technik Gmbh & Co. Kg Erdbohrvorrichtung
WO2017048566A1 (en) 2015-09-15 2017-03-23 C.B. Fleet Company, Incorporated Bisacodyl compositions and delivery apparatus
CN109984993A (zh) * 2018-01-03 2019-07-09 药大制药有限公司 一种提升比沙可啶栓质量的处方及制备方法
WO2022219573A2 (en) * 2021-04-15 2022-10-20 Rolling Pastures Pte. Ltd. Microencapsulation wall material, suspension core capsule, edible capsule with electronics, methods and a production system for producing the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE818022C (de) * 1950-05-05 1951-10-22 Otto Hellmann Papierkorb zur Aufnahme von Papier und Abfaellen
US2764590A (en) * 1952-03-17 1956-09-25 Thomae Gmbh Dr K Certain 4, 4'-disubstituted-diphenylpyridyl methanes and process
US3927195A (en) * 1974-01-31 1975-12-16 Lilly Industries Ltd Production of capsules
JPS5799521A (en) * 1980-12-11 1982-06-21 Eisai Co Ltd Solid composition containing bisacodyl
JPS59193816A (ja) * 1983-04-19 1984-11-02 Morishita Jintan Kk 腸溶性軟カプセルの製造法
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
JPS6320409A (ja) * 1986-07-15 1988-01-28 Nippon Kokan Kk <Nkk> 取鍋精錬方法
US4810707A (en) * 1987-02-25 1989-03-07 Meditech Pharmaceuticals, Inc. Herpes simplex treatment
JPS63258815A (ja) * 1987-04-16 1988-10-26 Kiyuushin Seiyaku Kk ビサコジル含有固形組成物
JPH0672106B2 (ja) * 1987-04-22 1994-09-14 花王株式会社 緩下剤組成物
JP2782691B2 (ja) * 1987-09-29 1998-08-06 ワーナー−ランバート・コンパニー 腸溶製剤の安定化
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
DE3818022C2 (de) * 1988-05-24 1994-04-28 Guenter Stephan Weichgelatinekapsel
JPH0818971B2 (ja) * 1989-02-16 1996-02-28 ブリティッシュ・テクノロジー・グループ・リミテッド 投与製剤
GB8903564D0 (en) * 1989-02-16 1989-04-05 Rashid Abdul Drug dispensing device
GB9004702D0 (en) * 1990-03-02 1990-04-25 Polysystems Limited Dispensing device

Also Published As

Publication number Publication date
CA2156726C (en) 2000-10-17
GR3036042T3 (en) 2001-09-28
DK0686034T3 (da) 2001-08-27
JP3725539B2 (ja) 2005-12-14
US5670158A (en) 1997-09-23
PL310355A1 (en) 1995-12-11
CN1047075C (zh) 1999-12-08
SK104895A3 (en) 1996-06-05
BR9405836A (pt) 1996-01-16
HU9502492D0 (en) 1995-10-30
CZ286051B6 (cs) 1999-12-15
WO1994018973A1 (en) 1994-09-01
DE69427466D1 (de) 2001-07-19
EP0686034B1 (en) 2001-06-13
HUT72975A (en) 1996-06-28
IL108705A (en) 1998-04-05
JPH08509958A (ja) 1996-10-22
PT686034E (pt) 2001-10-30
CA2156726A1 (en) 1994-09-01
DE69427466T2 (de) 2002-04-25
ATE201991T1 (de) 2001-06-15
CN1118571A (zh) 1996-03-13
EP0686034A1 (en) 1995-12-13
ES2157253T3 (es) 2001-08-16
PL176846B1 (pl) 1999-08-31
IL108705A0 (en) 1994-05-30
AU6251094A (en) 1994-09-14
CZ204995A3 (en) 1996-04-17

Similar Documents

Publication Publication Date Title
GR3036042T3 (en) Bisacodyl dosage form
HK1036018A1 (en) Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient il-6 antagonists
MXPA03008760A (es) Agentes terapeuticos para enfermedades inflamatorias de los intestinos.
DE69205971D1 (de) Orale dosierungsform mit verzögerter wirkstoffabgabe für die behandlung von intestinalen krankheiten.
ATE213936T1 (de) Pharmazeutische dosisform mit mehrfacher darmlöslicher polymerbeschichtung zur wirkstoffabgabe im kolon
ATE234079T1 (de) Pharmazeutische dosierungsform mit mehrfachen enterischen polymer-überzügenzur abgabe im kolon
NZ502445A (en) Control of acidic gut syndrome
HU9202808D0 (en) Improvement of down-regulqtion of autoimmunic diseases by means of oral dosing of autoantigenes
ATE260646T1 (de) Schnell zerfallende orale dosierungsform
AU2003243545A8 (en) Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
KR900015724A (ko) 메베버린 용량 형태
ES2149733T1 (es) Composicion farmaceutica oral con liberacion modificada que contiene 5-asa y metodo para el tratamiento de enfermedades intestinales.
CA2032475A1 (en) Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
CO4130184A1 (es) Forma de dosificacion de bisacodyl
HU9300244D0 (en) Method for producing chemotherapeutical agent of antitumourous effect originated of plants and medical preparatives containing it
JPS577422A (en) Crocosmia aurea &#34;plach&#34;
SE9003096D0 (sv) Device for administering a physiologically active substance to the gastro-intestinal tract
Rennie The persistence of African swine fever virus in the argasid tick Ornithodoros moubata.
IL124730A (en) Compositions for the treatment of gastrointestinal disorders comprising a bismuth compound and one or more antimicrobials, and the use of bismuth and an antimicrobial compound for the preparation of such compositions
Lamberti et al. Answer: A Strange Case of Parkinsonism in a Gastroenterologist
JPS6438027A (en) Remedy for cancer
ES8706028A1 (es) Procedimiento de preparacion de nuevas composiciones sinergeticas antimicrobianas que contienen aritetraciclina y un acido organico de acitividad antimicrobiana.
Quarto et al. On epidemiology of Yersinia enterocolitica. Note II. Research carried out on cattle farms.
Faro et al. Study of Trimethoprim/Sulfamethoxypyrazine Association in the Treatment of Pneumonia.
Tsymbalar et al. Pathogenetic treatment in combined therapy of patients with tuberculous pleurisy.